Harrow Health Inc (HROW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harrow Health Inc (HROW) has a cash flow conversion efficiency ratio of -0.657x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.76 Million) by net assets ($14.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Harrow Health Inc (HROW) total market value for the company's overall valuation and market capitalisation.
Harrow Health Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Harrow Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HROW share price today for real-time trading data and today's change.
Harrow Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harrow Health Inc ranked by their cash flow conversion efficiency. Review Harrow Health Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sam Hwa Capaci
KO:001820
|
0.011x |
|
Platinum Asset Management Ltd
AU:PTM
|
0.138x |
|
Oriental Holdings Bhd
KLSE:4006
|
0.060x |
|
Yubico AB
ST:YUBICO
|
0.075x |
|
Jastrzebska Spotka Weglowa SA
WAR:JSW
|
-0.112x |
|
Ecovyst Inc
NYSE:ECVT
|
0.087x |
|
Cymbria Corporation
TO:CYB
|
0.001x |
|
Icade SA
PA:ICAD
|
0.027x |
Annual Cash Flow Conversion Efficiency for Harrow Health Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Harrow Health Inc from 2005 to 2025. Also see Harrow Health Inc assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.09 Million | $43.86 Million | 0.842x | +362.83% |
| 2024-12-31 | $69.30 Million | $-22.20 Million | -0.320x | -684.06% |
| 2023-12-31 | $70.00 Million | $3.84 Million | 0.055x | -13.50% |
| 2022-12-31 | $26.89 Million | $1.71 Million | 0.063x | -86.36% |
| 2021-12-31 | $10.93 Million | $5.08 Million | 0.465x | +1233.89% |
| 2020-12-31 | $26.83 Million | $-1.10 Million | -0.041x | -218.34% |
| 2019-12-31 | $27.42 Million | $950.00K | 0.035x | +24.83% |
| 2018-12-31 | $24.75 Million | $687.00K | 0.028x | +100.82% |
| 2017-12-31 | $2.62 Million | $-8.80 Million | -3.366x | -93.07% |
| 2016-12-31 | $6.43 Million | $-11.21 Million | -1.744x | -121.67% |
| 2015-12-31 | $-1.39 Million | $-11.14 Million | 8.045x | +1029.39% |
| 2014-12-31 | $8.15 Million | $-7.06 Million | -0.866x | -194.69% |
| 2013-12-31 | $15.11 Million | $-4.44 Million | -0.294x | -54.49% |
| 2012-12-31 | $10.00 Million | $-1.90 Million | -0.190x | -211.02% |
| 2011-12-31 | $-1.70 Million | $-291.16K | 0.171x | -92.26% |
| 2010-12-31 | $-1.04 Million | $-2.30 Million | 2.214x | +135.78% |
| 2009-12-31 | $577.21K | $-3.57 Million | -6.186x | -1016.35% |
| 2008-12-31 | $4.57 Million | $-2.53 Million | -0.554x | -9.67% |
| 2007-12-31 | $3.49 Million | $-1.76 Million | -0.505x | +82.02% |
| 2006-12-31 | $21.35K | $-60.00K | -2.810x | -145.49% |
| 2005-12-31 | $34.99K | $-40.06K | -1.145x | -- |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, in… Read more